Small Molecule Innovator CDMO Market Growth & Trends
The global small molecule innovator CDMO market size is expected to reach USD 74.9 billion by 2030, expanding at 6.4% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. There is a growing interest among pharmaceutical companies in outsourcing to support core competencies such as sales, marketing, and others, due to associated cost savings. Furthermore, outsourcing enables companies to further progress core competencies such as drug development and manufacturing activities. Hence, expansions by small molecule CDMOs in recent years promise major support for the market growth in the upcoming years.
Small molecules continue to play an important role in the development of new treatments globally. Specialty medicines are increasingly driving global pharmaceutical manufacturing growth, particularly in developed markets with small molecule application accounting for over half of specialty sales. The application of small molecules are becoming increasingly complex.
Small Molecule Innovator CDMO Market Report Scope
Report Attribute | Details |
Market Size value in 2023 | USD 48.6 billion |
Revenue forecast in 2030 | USD 74.9 billion |
Growth Rate | CAGR of 6.4% from 2023 to 2030 |
Base year for estimation | 2022 |
Historical data | 2018 - 2021 |
Forecast period | 2023 - 2030 |
The majority of solutions in the regulatory approval pipeline are made up of poorly soluble compounds that would require enabling technology to progress to clinical trials and beyond. As therapy targets and focus areas become more specific, creating target product profiles has become increasingly difficult. Failure to achieve appropriate bioavailability is an additional stumbling block in the development of many new chemical entities. These factors are expected to support the overall market growth.
The geriatric population is expected to witness a surge in the coming years. For instance, the WHO estimates that there will be more than 2 billion people aged 60 and over by 2050. This would create a lot of opportunities for the development of new small-molecule drugs, which is expected to support the market growth in the post-pandemic period.
Request a free sample copy or view report summary: Small Molecule Innovator CDMO Market Report
Small Molecule Innovator CDMO Market Report Highlights
- The small molecule API segment is anticipated to register the fastest CAGR of 6.7% over the forecast period. This growth can primarily be attributed to the high approval rate of NME small molecules by regulatory agencies
- The clinical stage segment dominated the market with 55.1% of the revenue share in 2022. CDMOs offer specialized expertise, time-saving, and cost-efficiency during clinical procedures. This is expected to augment the segmental growth over the forecast period
- Based on customer type, the pharmaceutical companies segment held the largest share of 93.9% in 2022. The growing focus on pharmaceutical companies to focus on core competencies, such as sales and adoption of expansion strategies by CDMOs for manufacturing small molecule drugs, are promoting the segment’s market growth
- The oncology segment dominated the market with 41.8% of the revenue share in 2022, and it is anticipated to register the fastest CAGR of over 7.0% over the forecast period. A significant number of oncology drugs in the regulatory approval pipeline is one of the major factors supporting the segment’s growth
- Asia Pacific is anticipated to register the fastest CAGR of 7.2% over the forecast period. Due to significantly cheaper manufacturing costs than in North America & Europe and favorable regulations guiding innovation
Access Press Release@ https://www.grandviewresearch.com/press-release/global-small-molecule-innovator-cdmo-market
Small Molecule Innovator CDMO Market Segmentation
Grand View Research has segmented the global small molecule innovator CDMO market based on product, stage type, customer type, therapeutic area, and region:
Small Molecule Innovator CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)
- Small Molecule API
- Small Molecule Drug Product
- Oral solid dose
- Semi-Solid Dose
- Liquid Dose
- Others
Small Molecule Innovator CDMO Stage Type Outlook (Revenue, USD Million, 2018 - 2030)
- Preclinical
- Clinical
- Phase I
- Small
- Medium
- Large
- Phase II
- Small
- Medium
- Large
- Phase III
- Small
- Medium
- Large
- Commercial
- Phase I
Small Molecule Innovator CDMO Customer Type Outlook (Revenue, USD Million, 2018 - 2030)
- Pharmaceutical
- Small
- Medium
- Large
- Biotechnology
Small Molecule Innovator CDMO Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
- Cardiovascular disease
- Oncology
- Respiratory disorders
- Neurology
- Metabolic disorders
- Infectious disease
- Others
Small Molecule Innovator CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- US.
- Canada
- Europe
- UK.
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- India
- Japan
- China
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
List of Key Players of Small Molecule Innovator CDMO Market
- Piramal Pharma Solutions
- CordenPharma International
- Wuxi AppTec
- Cambrex Corporation
- Recipharm AB
- Pantheon (Thermo Fisher Scientific)
- Lonza
- Catalent Inc.
- Siegfried Holding AG
- Boehringer Ingelheim
- Labcorp Drug Development
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment